R. Wardi

Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

E. Leray, G. Edan, T. Anani, 2011, Journal of the Neurological Sciences.

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP)

G. Edan, D. Laplaud, D. Veillard, 2016 .

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP)

D. Laplaud, D. Veillard, V. Deburghgraeve, 2020 .

Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial.

G. Edan, D. Laplaud, K. Chevreul, 2021, Revue neurologique.

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial

G. Edan, D. Laplaud, D. Veillard, 2015, The Lancet.